Navigation Links
Phase IV Multi-center Clinical Study of Kutai Concludes in Nanjing
Date:3/24/2009

REVIEW OF RESULTS CONFIRM SAFETY AND EFFICACY FOR ROOM TEMPERATURE STORAGE

NANTONG CITY, China, March 24 /PRNewswire-FirstCall/ -- Sinobiopharma, Inc. (OTC Bulletin Board: SNBP) is pleased to announce that its patented version of Cisatracurium besylate, a pre-surgical skeletal muscle relaxant marketed as Kutai in China, has successfully concluded its Phase IV Clinical Study.

The multi-center Phase IV Clinical Study investigated the safety and effectiveness of Kutai's use at room temperature. The after-market study, supported by the National Multi-center Clinical plan, was concluded successfully on September 2, 2008.

Kutai is a non-depolarizing skeletal muscle relaxant for intravenous administration. Compared to other neuromuscular blocking agents, it is intermediate in its onset and duration of action.

More than 30 clinical experts from seven participating medical centers within China gathered in Nanjing for a conference to review the results of the Phase IV of the Kutai Multi-center clinical study project.

Ms. Xinming Wu, Chief anesthetist of No.1 Hospital of Chinese Peking University Anesthesia Department, presided over the conference and delivered a summary report of the Phase IV project. Xuejun Chen, Sinobiopharma's vice president of sales was also in attendance and expressed Sinobiopharma's thanks to the participating experts for their commitment to research on Kutai.

Sinobiopharma has established a highly specialized professional team of clinical trial monitors as part of the project to keep close surveillance on the patients. The manager of Sinobiopharma's Clinical Research Department, Mr. Lei Wang, reported on the Phase IV project clinical monitoring outcomes.

The experts' consensus was that the Phase IV study established Kutai as safe and effective for room temperature storage. The year-long clinical research project showed no significant differences between Kutai and imported Cisatracurium besylate, and no significant differences for Kutai safety and effectiveness when stored at either room temperature or a lower temperature.

All the participating parties followed the study design and promote inter-communication to ensure compliance with Good Clinical Practice (GCP).

About Sinobiopharma

Sinobiopharma, Inc. is a fully integrated and highly innovative biotechnology company engaged in the research and development, manufacture and marketing of biopharmaceutical products in China, the world's fastest growing pharmaceutical market. Known as Dong Ying (Jiangsu) Pharmaceutical Co. Ltd. in China, the Company's current therapeutic focus is on anesthesia-assisted agents and cardiovascular drugs.

FORWARD LOOKING STATEMENTS

This news release may include "forward-looking statements" regarding Sinobiopharma, Inc., and its subsidiaries, business and project plans. Such forward looking statements are within the meaning of Section 27A of the Securities Act of 1933, as amended, and section 21E of the United States Securities and Exchange Act of 1934, as amended, and are intended to be covered by the safe harbor created by such sections. Where Sinobiopharma, Inc. expresses or implies an expectation or belief as to future events or results, such expectation or belief is believed to have a reasonable basis. However, forward-looking statements are subject to risks, uncertainties and other factors, which could cause actual results to differ materially from future results expressed, projected or implied by such forward-looking statements. Sinobiopharma, Inc. does not undertake any obligation to update any forward-looking statement, except as required under applicable law.


'/>"/>
SOURCE Sinobiopharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Abbott Advances Its Revolutionary Fully Bioabsorbable Drug Eluting Stent With Initiation of Next Phase of Clinical Trial
2. Radius Initiates Phase 2a Clinical Trial of RAD1901 in Menopausal Hot Flashes
3. Calixa Therapeutics Announces Positive Phase 1 Results for CXA-101, a Novel Intravenous Cephalosporin Antibiotic with Excellent Anti-Pseudomonal Activity
4. Phase III Trial Showed Investigational Compound Arzoxifene Was Superior to Evista(R) (raloxifene HCl) in Increasing BMD in Postmenopausal Women with Osteoporosis
5. Micromet Has Started a New Phase 2 Trial with Adecatumumab in Colorectal Cancer Patients
6. Innocoll Announces Dosing of Last Patient in Second US Phase 3 Clinical Trial to Investigate GENTAMICIN SURGICAL IMPLANT for Prevention of Surgical Site Infections in Colorectal Surgery Patients
7. Cephalon Announces Positive Results From a Phase Two Study of NUVIGIL in Bipolar Depression
8. Walter Reed Army Medical Center offers HIFU for Qualifying Men with Locally Recurrent Prostate Cancer in a Phase III Clinical Trial
9. Healthpoint Initiates Phase II, Dose-Finding Study to Evaluate Effectiveness of a Unique Cell Based Therapy in Venous Leg Ulcers
10. DURECT Reports Positive Phase IIb Data from TRANSDU(TM)-Sufentanil Clinical Program
11. Innocoll Announces Dosing of Last Patient in US Phase 3 Clinical Trial to Investigate GENTAMICIN SURGICAL IMPLANT for Prevention of Surgical Site Infections in Cardiac Surgery Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/28/2017)... Sept. 28, 2017 Hill-Rom Holdings, Inc. (NYSE: ... conference call and webcast on Friday, November 3, 2017, ... and ending at approximately 8:30 a.m. (CDT) / 9:30 ... company,s 2017 financial performance and guidance for 2018, Hill-Rom ... to enhance operational performance, and long-range financial outlook through ...
(Date:9/25/2017)... Sept. 25, 2017  EpiVax, Inc., a leader ... and immune-engineering today announced the launch of EpiVax ... of personalized therapeutic cancer vaccines. EpiVax has provided ... access to enabling technologies to the new precision ... lead EpiVax Oncology as Chief Executive Officer. Gad ...
(Date:9/19/2017)... , Sept. 19, 2017   ZirMed Inc ., a ... today announced that it has been ranked #1 by its ... Book™ Rankings 2017 User Survey. ZirMed was recognized as ... large hospitals and medical centers over 200 beds and holds ... healthcare technology user survey history. ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... ... While it’s often important to take certain medications during the night, finding ... identified a solution. , She developed a prototype for MOTION LIGHT-UP PILL BOX to ... the need to turn on a light when taking medication during the night, allowing ...
(Date:10/13/2017)... ... October 13, 2017 , ... PurhealthRX , a leading Health and Nutrition ... the Purzorb™process to full spectrum CBD oil will revolutionize the rapidly growing CBD market ... can be easily incorporated into liquid products, while reducing costs to end users. , ...
(Date:10/13/2017)... Shelton, CT (PRWEB) , ... October 13, 2017 , ... ... and long-term care services, staged a mock evacuation of the facility as part of ... Department, Shelton Fire Department, Echo Hose EMS and Shelton City Emergency Manager, as well ...
(Date:10/13/2017)... ... ... Ellevate Network, the leading network for professional women, brought together some of ... their inaugural Summit in New York City in June. The event was livestreamed with ... 3 million. To watch the Mobilize Women video, click here . , ...
(Date:10/13/2017)... ... ... Talented host, actor Rob Lowe, is introducing a segment ... of "Success Files," which is an award-winning educational program broadcasted on PBS Member ... with passion and integrity. , Sciatica occurs when the sciatic nerve in the ...
Breaking Medicine News(10 mins):